Brandon Hudgins Receives 2017 Rare Impact Award

The National Organization for Rare Disorders (NORD) today announced the people, organizations, and innovators who will be honored at the 2017 Rare Impact Awards on May 18 in Washington, D.C.

The Rare Impact Awards is a charity event that celebrates those who are boldly leading efforts to make a difference for people living with rare diseases.  The benefit is hosted by NORD, the leading independent nonprofit organization representing the 30 million Americans with rare diseases, and brings together supporters of the organization’s mission.

“There are 30 million Americans living with rare diseases and more than half of these people are children,” said Peter L. Saltonstall, president and CEO of NORD.  “This evening will showcase the remarkable stories of those are who creating a brighter future in which every person with a devastating medical condition has access to a cure.”

The 2017 honorees include patients Ellie McGinn, Christine Grube, and Brandon Hudgins; caregiver and White House Precision Medicine Initiative appointee Matthew Might, Ph.D.; patient and advocate Beth Nguyen, R.N.; researchers and clinicians Robert Desnick, Ph.D., M.D., Frederick Kaplan, M.D., and Cynthia Tifft, M.D.; national health leaders Rep. Diana DeGette (D-CO) and Sen. Johnny Isakson (R-GA); A Twist of Fate – ATS, a nonprofit patient organization serving the Arterial Tortuosity Syndrome community; and industry innovators Advanced Accelerator Applications USA, Biogen, CSL Behring, Intercept Pharmaceuticals, Jazz Pharmaceuticals, and Sarepta Therapeutics.

Nationally touring music artist and winner of NPR Music’s 2016 Tiny Desk Contest, Gaelynn Lea, will perform original songs during the event in support of the millions of people with rare diseases.  In addition to her work as a performing and recording artist, Gaelynn is a public speaker who uses her music as a platform to advocate for people with disabilities and to promote positive social change. The David Bach Consort will also perform.

The Rare Impact Awards serves as a NORD’s signature fundraiser to support the organization’s mission of providing education, advocacy, research, and patient support for the 1 in 10 Americans who are battling rare diseases. More than 350 distinguished guests are expected to attend.
The Rare Impact Awards serves as a NORD’s signature fundraiser to support the organization’s mission of providing education, advocacy, research, and patient support for the 1 in 10 Americans who are battling rare diseases. More than 350 distinguished guests are expected to attend.

The event is presented with support from benefactor sponsors Sanofi Genzyme and Shire and diamond sponsors BioMarin Pharmaceutical and CSL Behring.

Vasculitis Foundation

The Vasculitis Foundation is the international organization for patients with vasculitis, their families, friends and the health care professionals who care for them.


VF Announces 2018 V-RED Awardees

The Vasculitis Foundation is pleased to announce Dr. Linda Brady, a pediatrician with Vanderbilt, is the winner of its 2018 Recognizing Excellence in Diagnostics (V-RED) Award.  The award is presented annually to more »

VF Celebrates Vasculitis Awareness Month 2018

The Vasculitis Foundation, the world’s largest organization dedicated to providing advocacy, education and support for people with vasculitis, announces the launch of Vasculitis Awareness Month (May 2018), an annual effort more »

#GivingTuesday Matching Gift Challenge

#GivingTuesday is a global day of giving fueled by the power of social media and collaboration.  This year your donation can go even further with our generous matching gift challenge! more »


Introducing our 2017-2018 VCRC-VF Fellow

Kaitlin Quinn, MD, is the recipient of the 2017 VCRC-VF Fellowship.  She received her medical degree from New York Medical College in Valhalla, New York.   She completed her Internal Medicine more »

FDA Approves Genentech’s Actemra® for Giant Cell Arteritis

Genentech, a member of the Roche Group, announced today (May 22, 2017) that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) subcutaneous injection for the treatment of more »